

Supplemental information

**miR-204 silencing reduces mitochondrial
autophagy and ROS production in a murine
AD model via the TRPML1-activated STAT3 pathway**

Lu Zhang, Yu Fang, Xinyu Zhao, Yake Zheng, Yunqing Ma, Shuang Li, Zhi Huang, and Lihao Li

Table S1 Primer sequences of RT-qPCR

Target	Sequence
TRPML1	F: 5'-GGAGTTGTCAATGGCTGGT-3' R: 5'-GAATGACACCGACCCAGACT-3'
miR-204	F: 5'-GGTTCCCTTGTCATCC-3' R: 5'-TGCCTGTCGTGGAGTC-3'
U6	F: 5'-GCTTCGGCAGCACATATACTAAAAT-3' R: 5'-CGCTTCACGAATTGCGTGTCA-3'
GAPDH	F: 5'-GCTTCGGCAGCACATATACTAAAAT-3' R: 5'-AGATGATGACCCTTGGCTC-3'

RT-qPCR: reverse transcription quantitative polymerase chain reaction; TRPML1: transient receptor potential mucolipin-1; miR: microRNA; GAPDH: glyceraldehyde-3-phosphate dehydrogenase; F: forward; R: reverse.




Fig. S1 The off-target efficacy of shRNAs against TRPML1 (sh-TRPML1-1, sh-TRPML1-2, sh-TRPML1-3)




Fig. S2 Co-localization of mitochondria and lysosomes after different treatment detected by Mitotracker (green) and Lysotracker (red) staining. A: co-localization of mitochondria and lysosomes after TRPML1 overexpression treatment. B: co-localization of mitochondria and lysosomes after miR-204 inhibitor ($0.5 \mu\text{M}$, $5 \mu\text{M}$, $10 \mu\text{M}$, and $15 \mu\text{M}$) and sh-TRPML1 treatment. C: co-localization of mitochondria and lysosomes after CLN and sh-TRPML1 treatment. The yellow color indicates the merging of Mitotracker and Lysotracker.




Fig. S3 HE staining was used to detect the pathological changes of hippocampus in mice.